Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Corcept Therapeutics Inc (NASDAQ: CORT) closed the day trading at $35.78 up 2.37% from the previous closing price of $34.95. In other words, the price has increased by $2.37 from its previous closing price. On the day, 3.82 million shares were traded. CORT stock price reached its highest trading level at $36.9 during the session, while it also had its lowest trading level at $34.28.
Ratios:
For a better understanding of CORT, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.15. For the most recent quarter (mrq), Quick Ratio is recorded 3.07 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 06 ’26 when Guyer William bought 20,000 shares for $34.95 per share.
Guyer William sold 20,000 shares of CORT for $1,601,526 on Dec 02 ’25. The Chief Development Officer now owns 1,235 shares after completing the transaction at $80.08 per share. On Dec 01 ’25, another insider, Maduck Sean, who serves as the insider of the company, sold 20,000 shares for $79.52 each. As a result, the insider received 1,590,490 and left with 7,904 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 3770200320 and an Enterprise Value of 3343049984. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.88, and their Forward P/E ratio for the next fiscal year is 63.06. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 5.95. Its current Enterprise Value per Revenue stands at 4.51 whereas that against EBITDA is 50.111.
Stock Price History:
The Beta on a monthly basis for CORT is 0.24, which has changed by -0.32385373 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $32.99. The 50-Day Moving Average of the stock is -52.52%, while the 200-Day Moving Average is calculated to be -51.39%.
Shares Statistics:
Over the past 3-months, CORT traded about 1.37M shares per day on average, while over the past 10 days, CORT traded about 4074330 shares per day. A total of 105.12M shares are outstanding, with a floating share count of 92.90M. Insiders hold about 11.68% of the company’s shares, while institutions hold 74.67% stake in the company. Shares short for CORT as of 1765756800 were 10108719 with a Short Ratio of 7.36, compared to 1763078400 on 10166733. Therefore, it implies a Short% of Shares Outstanding of 10108719 and a Short% of Float of 12.989999999999998.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Corcept Therapeutics Inc (CORT).The consensus estimate for the next quarter is $0.05, with high estimates of $0.34 and low estimates of -$0.12.
Analysts are recommending an EPS of between $1.18 and $0.57 for the fiscal current year, implying an average EPS of $0.87. EPS for the following year is $0.69, with 6.0 analysts recommending between $1.9 and -$0.93.
Revenue Estimates
5 analysts predict $246.11M in revenue. The current quarter. It ranges from a high estimate of $265.72M to a low estimate of $197.3M. As of. The current estimate, Corcept Therapeutics Inc’s year-ago sales were $181.89MFor the next quarter, 5 analysts are estimating revenue of $200.83M. There is a high estimate of $227.96M for the next quarter, whereas the lowest estimate is $166.2M.
A total of 5 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $825M, while the lowest revenue estimate was $756.6M, resulting in an average revenue estimate of $805.38M. In the same quarter a year ago, actual revenue was $675.04MBased on 5 analysts’ estimates, the company’s revenue will be $1.05B in the next fiscal year. The high estimate is $1.26B and the low estimate is $843.1M.
